Lantern Pharma Inc.
NASDAQ:LTRN · NASDAQ Capital Market
-$0.19 today
Vol 0.16M · Avg 0.68M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.3%
avg 48.5%
ROIC
-0.3%
avg 47.2%
ROA
-0.2%
avg -92.7%
Analysis
ROA is currently the strongest return metric at -0.2% versus its period average of -92.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Panna Sharma | President, Chief Executive Officer & Director | $763,750.00 | — | 55 | $70,000.00 | 0.55% |
David R. Margrave | Chief Financial Officer & Secretary | $540,780.00 | — | 65 | $25,000.00 | 0.20% |
Kishor Gopaldas Bhatia | Chief Scientific Officer & Scientific Consultant | $222,024.00 | — | 71 | $10,000.00 | 0.08% |
Marc C. Chamberlain | Chief Medical Officer of Starlight Therapeutics | — | — | — | — | — |
Peter L. Nara | Co-Founder & Advisor | — | — | — | — | — |
Ernest Kitt | Head of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$200,001.28
Sells
2
$220,389.76
Net Sentiment
$20,388.48
Net selling
Most Active
Schalop Lee Troy
2 transactions
Analysis
Insiders reported 2 buys worth $200,001.28 and 2 sells worth $220,389.76 over the last 12 months. That adds up to net selling of $20,388.48. Schalop Lee Troy was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
MAIA Biotechnology, Inc.
AMEX:MAIA
$79.04M
LAVA Therapeutics N.V.
LVTX
$45.77M
Elutia Inc.
ELUT
$42.44M
Annovis Bio, Inc.
ANVS
$35.02M
Actinium Pharmaceuticals, Inc.
ATNM
$31.69M
RenovoRx, Inc.
RNXT
$31.41M
Tvardi Therapeutics, Inc.
TVRD
$24.77M
CalciMedica, Inc.
CALC
$13.70M
BioAtla, Inc.
BCAB
$4.87M
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$2.35M
Who manages LTRN?
Lantern Pharma Inc. (LTRN) lists 6 active executives. The top listed executive is Kishor Gopaldas Bhatia, Chief Scientific Officer & Scientific Consultant.
Are LTRN insiders buying or selling?
Recent insider activity shows net buying of $15.34B.
Explore More
Continue the stock analysis
Jump to another research area for this company.